Immunogenicity and safety of quadrivalent human papillomavirus types 6/11/16/18 recombinant vaccine in chronic kidney disease stage IV, v and VD

Nephrology Dialysis Transplantation

Volumn 32, Issue 1, 2017, Pages 132-136

  Praditpornsilpa, Kearkiat ^a   Kingwatanakul, Pornchai ^a   Deekajorndej, Tawatchai ^a   Rianthavorn, Pornpimol ^a   Susantitaphong, Paweena ^a   Katavetin, Pisut ^a   Tiranathanakul, Khajohn ^a   Srisawat, Nattachai ^a   Tungsanga, Kriang ^a   Eiam Ong, Somchai ^a   Townamchai, Natavudh ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cancer; CKD; HPV vaccine

Indexed keywords

EPITOPE; IMMUNOLOGICAL ADJUVANT; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; CHILD; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENOTYPE; HUMAN; IMMUNOASSAY; IMMUNOLOGICAL MONITORING; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PROSPECTIVE STUDY; REPEATED DRUG DOSE; UNSPECIFIED SIDE EFFECT; VACCINATION; VACCINE IMMUNOGENICITY; BLOOD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RENAL INSUFFICIENCY, CHRONIC; THAILAND; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNOASSAY; MALE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; THAILAND; VACCINATION; YOUNG ADULT;

EID: 85016184657     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv444     Document Type: Article

References (24)

1. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res 2002; 89: 183-190
2. Gallison ML, Chaturvedi AK, Lowy DR. HPV prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008; 113 (10 Suppl): 3036-3046
3. Sanjosé Sd, Diaz M, Castellsagué X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007; 7: 453-459
4. Winer RL, Lee SK, Hughes JP et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university student. Am J Epidemiol 2003; 157: 218-226
5. Ferlay J, Shin H-R, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917
6. Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet 1999; 354: 93-99
7. Vajdic CM, McDonald SP, McCredie MRE et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 2823-2831
8. Poland GA, Jacobson RM, Koutsky LA et al. Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: A 2-year randomized controlled clinical trial.Mayo Clin Proc 2005; 80: 601-610
9. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927
10. Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: A combined analysis of four randomised clinical trials. Lancet 2007; 369: 1861-1868
11. Joura EA, Leodolter S, Hernandez-Avila M et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-likeparticle vaccine against high-grade vulval and vaginal lesions: A combined analysis of three randomised clinical trials. Lancet 2007; 369: 1693-1702
12. Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl JMed 2007; 356: 1928-1943
13. Kurts C, Panzer U, Anders HJ et al. The immune system and kidney disease: basic concepts and clinical Implications. Nat Rev Immunol 2013; 13: 738-753
14. Recommendations for preventing transmission of infections among chronic hemodialysis patients.MMWR Recomm Rep 2001; 50 (RR-5): 1-43
15. Praditpornsilpa K, Townamchai N, Chaiwatanarat T et al. The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations. Nephrol Dial Transplant 2011; 26: 2780-2785
16. Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed Luminex assay. Clin Diagn Lab Immunol 2003; 10: 108-115
17. Dias D, Doren JV, Schlottmann S et al. Optimization and validation of a multiplexed Luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005; 12: 959-969
18. Orozco JJ, Carter JJ, Koutsky LA et al. Humoral immune response recognizes a complex set of epitopes on human papillomavirus type 6 L1 capsomers. J Virol 2005; 79: 9503-9514
19. Merck & Co., Inc. GARDASIL Product Information. Whitehouse Station, NJ:Merck & Co., Inc., 2009
20. Suzich JA, GhimSJ, Palmer-Hill FJ. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-11557
21. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine 2006; 24 (Suppl 3): S106-S113
22. Mast EE,Margolis HS, Fiore AE et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54 (RR-16): 1-31
23. Villa LL, Costa RLR, Petta CA et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of followup. Br J Cancer 2006; 95: 1459-1466
24. Olsson S-E, Vulla LL, Costa RLR et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007; 25: 4931-4939